Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

MONTREAL, QC, Canada – May 20th, 2021

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of hospitalized patients with COVID-19. The study, which enrolled 240 patients across Canada and United States, is expected to report top-line results in Q3 2021.

Read more ...

Laurent Pharmaceuticals Provides Clinical Development Update

MONTREAL, QC, Canada – April 8th, 2021

  • Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 Patients
  • Completes Enrollment in Phase 2 APPLAUD Study in Patients with Cystic Fibrosis
  • Topline Results Expected in H2 2021 for both RESOLUTION and APPLAUD Studies

Read more ...


Laurent Pharmaceuticals to participate at BIO Digital 2021, June 10-11 & 14-18, 2021